# Obesity Medical Management > Obesity medical management for NEET-PG Medicine: Asian BMI cut-offs, pharmacotherapy with safety limits and bariatric surgery criteria for Indian practice. - Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/obesity-medical-management - Exam / course: NEET-PG · Subject: Medicine - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-08 - Last updated: 2026-10-08 - Reference basis: Harrison's Principles of Internal Medicine; Davidson's Principles and Practice of Medicine; ICMR Nutrient Requirements for Indians - How to cite: "Obesity Medical Management", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/obesity-medical-management ## Direct answer Obesity is a chronic disease defined by body mass index, and in South Asians the cut-offs are lower than WHO's standard thresholds because diabetes and hypertension appear at a lower BMI. Management starts with a structured lifestyle programme. Anti-obesity drugs or bariatric surgery follow when weight loss is inadequate or comorbidity is significant. ## What you must remember - **Asian BMI cut-offs:** Indian consensus statements commonly use overweight from about 23 kg/m2 and obesity from about 25 kg/m2, with 27.5 kg/m2 marking high risk, against WHO's 25 and 30. - **Waist circumference:** central obesity in South Asian adults is commonly taken as at least 90 cm in men and 80 cm in women. - **First-line treatment:** diet change, at least 150 minutes of moderate activity weekly and a target of 5 to 10 percent weight loss, which already improves glycaemia and blood pressure. - **Pharmacotherapy:** orlistat needs fat-soluble vitamin supplementation, phentermine with topiramate is limited by pregnancy and cardiovascular risk, and GLP-1 receptor agonists such as liraglutide and semaglutide are widely used. - **Absolute contraindication:** personal or family history of medullary thyroid carcinoma or MEN type 2 excludes GLP-1 receptor agonists. - **Bariatric criteria:** classically BMI of 40 or more, or 35 or more with serious comorbidity; newer ASMBS and IFSO guidance offers surgery from 35 regardless of comorbidity, and Asian guidance lowers the threshold further, especially with diabetes. - **Secondary obesity:** check thyroid function, cortisol excess, hypothalamic disease and drugs such as steroids and antipsychotics before attributing weight gain to lifestyle alone. ## Worked example: a 46-year-old with rising weight and diabetes A 46-year-old man has a BMI of 31, a waist of 98 cm, hypertension and an HbA1c of 7.2 percent. The plan moves in stages, with each review deciding the next step. 1. **Confirm and screen:** The measurements are confirmed and secondary causes are screened, starting with TSH and a morning cortisol if features suggest excess. 2. **Start lifestyle change:** A structured lifestyle programme with a dietitian is set, with review at about three months. 3. **Add pharmacotherapy if weight loss stalls:** If weight has fallen by less than 5 percent by then, pharmacotherapy is added, and with diabetes a GLP-1 receptor agonist is a reasonable choice after the contraindications are excluded. 4. **Reassess at six to twelve months:** Weight and comorbidity are reassessed then. If BMI rises to 35 or more with diabetes despite these measures, metabolic surgery is discussed. 5. **Consider the surgical options:** Sleeve gastrectomy and Roux-en-Y gastric bypass are the commonest procedures, and both often induce remission of type 2 diabetes. 6. **Aim for sustained loss:** The aim is sustained loss rather than a single rapid result, because weight regain after stopping drugs is common. ## Where the examiner tests your numbers The commonest errors involve numbers and drug safety. - **Trap:** using WHO's BMI thresholds for an Indian patient — **Correct:** Indian cut-offs flag risk from BMI 23 and obesity from 25, which WHO's thresholds miss. - **Trap:** prescribing orlistat without a plan for vitamins — **Correct:** its fat malabsorption demands fat-soluble vitamin supplementation, while sibutramine is historical and withdrawn. - **Trap:** prescribing phentermine casually — **Correct:** it is sympathomimetic, so pregnancy, cardiovascular disease, hyperthyroidism and glaucoma exclude it. - **Trap:** using metformin as an obesity drug — **Correct:** it is not licensed for obesity alone in non-diabetic patients, although it is used for insulin resistance. The bariatric question tests whether comorbidity lowers the BMI threshold, and Asian guidance lowers it still. ## Frequently asked questions ### What BMI cut-off defines obesity in Indian adults? Indian consensus statements commonly define obesity from a BMI of about 25 kg/m2, and overweight from about 23 kg/m2, against WHO's standard obesity threshold of 30 kg/m2. A BMI of 27.5 kg/m2 and above is treated as high risk for diabetes and cardiovascular disease. ### Which anti-obesity drug is contraindicated in medullary thyroid carcinoma? GLP-1 receptor agonists such as liraglutide and semaglutide are contraindicated in medullary thyroid carcinoma and in MEN type 2, because of a rodent signal of thyroid C-cell tumours. Personal or family history of these conditions must be asked before starting any agent in this class. ### What are the criteria for bariatric surgery in obese adults? Bariatric surgery has classically been offered for a BMI of 40 kg/m2 or more, or 35 kg/m2 or more with serious comorbidity such as type 2 diabetes or sleep apnoea. Newer guidance and Asian guidance lower these thresholds, and surgery is considered only after structured medical management has been tried. ### Why is orlistat prescribed with vitamin supplements? Orlistat blocks pancreatic lipase, so fat absorption falls and fat-soluble vitamins A, D, E and K can be lost in the stool. Supplements taken at least two hours from the drug are advised to prevent deficiency during orlistat treatment. ### Which secondary causes must be excluded before treating obesity medically? Hypothyroidism, Cushing syndrome, hypothalamic disease and drug-induced weight gain from steroids or antipsychotics must be excluded before treating obesity medically. Missing a secondary cause means drug therapy may fail.